Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy

NCT03080116 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Neoadjuvant Therapy
Androgen Antagonists
Prostatectomy

Interventions

DRUG: ARN-509
DRUG: Degarelix
OTHER: Placebo

Sponsor

Universitaire Ziekenhuizen KU Leuven